Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology

Branchu, 2007, A decision-support tool for the formulation of orally active, poorly soluble compounds, Eur. J. Pharm. Sci., 32, 128, 10.1016/j.ejps.2007.06.005 Branham, 2012, Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement, Eur. J. Pharm. Biopharm., 80, 194, 10.1016/j.ejpb.2011.08.005 Cerdeira, 2012, Miconazole nanosuspensions: influence of formulation variables on particle size reduction and physical stability, Int. J. Pharm., 396, 210, 10.1016/j.ijpharm.2010.06.020 Chakraborty, 2009, Lipid – an emerging platform for oral delivery of drugs with poor bioavailability, Eur. J. Pharm. Biopharm., 73, 1, 10.1016/j.ejpb.2009.06.001 Choi, 2005, Role of polymeric stabilizers for drug nanocrystal dispersions, J. Curr. Appl. Phys., 5, 472, 10.1016/j.cap.2005.01.012 De Castro, C.-L., Mitchell, B.-S., 2002. In: Baraton, M.I. (Ed.), Synthesis, Functionalization and Surface Treatment of Nanoparticles. American Scientific Publishers, California, pp. 1–15. Eerdenbrugh, 2009, A screening study of surface stabilization during the production of drug nanocrystals, J. Pharm. Sci., 98, 2091, 10.1002/jps.21563 Ghosh, 2011, Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth, Int. J. Pharm., 409, 260, 10.1016/j.ijpharm.2011.02.051 Ghosh, I., Schenck, D., Bose, S., Ruegger, C., 2012. Optimization of formulation and process parameters for the production of 3 nanosuspension by wet media milling technique: effect of Vitamin E TPGS 4 and nanocrystal particle size on oral absorption. Eur. J. Pharm. Sci. (Early online). Grau, 2000, Nanosuspensions of poorly soluble drugs—reproducibility of small scale production, Int. J. Pharm., 196, 155, 10.1016/S0378-5173(99)00411-1 Hecq, 2005, Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine, Int. J. Pharm., 299, 167, 10.1016/j.ijpharm.2005.05.014 Hecq, 2006, Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base, Eur. J. Pharm. Biopharm., 64, 360, 10.1016/j.ejpb.2006.05.008 Juhnke, 2010, Accelerated formulation development for milled active pharmaceutical ingredients using a screening approach, Chem. Eng. Technol., 33, 1412, 10.1002/ceat.201000062 Junghanns, 2008, Nanocrystal technology, drug delivery and clinical applications, Int. J. Nanomed., 3, 295 Kawabataa, 2011, Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications, Int. J. Pharm., 420, 1, 10.1016/j.ijpharm.2011.08.032 Kawakami, 2006, Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents, Eur. J. Pharm. Sci., 28, 7, 10.1016/j.ejps.2005.11.012 Keck, 2006, Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation, Eur. J. Pharm. Biopharm., 62, 3, 10.1016/j.ejpb.2005.05.009 Kesisoglou, 2007, Nanosizing-oral formulation development and biopharmaceutical evaluation, Adv. Drug. Deliv. Rev., 59, 631, 10.1016/j.addr.2007.05.003 Lee, 2010, Hydrophilic and hydrophobic amino acid copolymers for nano-communition of poorly soluble drugs, Int. J. Pharm., 384, 173, 10.1016/j.ijpharm.2009.09.041 Lee, 2008, Characteristics of polymers enabling nano-communiotion of water-insoluble drugs, Int. J. Pharm., 355, 28, 10.1016/j.ijpharm.2007.12.032 Lipinski, 2000, Drug-like properties and the causes of poor solubility and poor permeability, J. Pharm. Toxicol. Met., 44, 235, 10.1016/S1056-8719(00)00107-6 Liu, 2011, Nanosuspensions of poorly soluble drugs: preparation and development by wet milling, Int. J. Pharm., 411, 215, 10.1016/j.ijpharm.2011.03.050 Merisko-Liversidge, 2008, Drug nanoparticles: formulating poorly water-soluble compounds, Toxicol. Pathol., 36, 43, 10.1177/0192623307310946 Merisko-Liversidge, 2010, Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology, Adv. Drug. Deliv. Rev., 63, 427, 10.1016/j.addr.2010.12.007 Miyakoa, 2010, Solubility enhancement of hydrophobic compounds by cosolvents: role of solute hydrophobicity on the solubilization effect, Int. J. Pharm., 393, 48, 10.1016/j.ijpharm.2010.03.059 Mou, 2011, Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility, Int. J. Pharm., 413, 237, 10.1016/j.ijpharm.2011.04.034 Müller, 2001, Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future, Adv. Drug. Deliv. Rev., 47, 3, 10.1016/S0169-409X(00)00118-6 Niwa, 2011, Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies – development of particle design method, Int. J. Pharm., 405, 218, 10.1016/j.ijpharm.2010.12.013 Owen, 2009, Anion effects on electrostatic charging of sterically stabilized, water insoluble drug particles, Int. J. Pharm., 368, 154, 10.1016/j.ijpharm.2008.10.004 Patravale, 2004, Nanosuspensions: a promising drug delivery strategy, J. Pharm. Pharmacol., 6, 827, 10.1211/0022357023691 Peltonen, 2010, Pharmaceutical nanocrystals by media milling: critical process parameters, particle fracturing and stabilization methods, J. Pharm. Pharmacol., 62, 1569, 10.1111/j.2042-7158.2010.01022.x Sharma, 2010, Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIVdrugs, Adv. Drug. Deliv. Rev., 62, 491, 10.1016/j.addr.2009.11.019 Sharma, 2011, Evaluation of a crystalline nanosuspension: polymorphism, process induced transformation and in vivo studies, Int. J. Pharm., 408, 138, 10.1016/j.ijpharm.2011.01.032 Stegemann, 2007, When poor solubility becomes an issue: from early stage to proof of concept, Eur. J. Pharm. Sci., 31, 249, 10.1016/j.ejps.2007.05.110 Van Eerdenbrugh, 2008, Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products, Int. J. Pharm., 364, 64, 10.1016/j.ijpharm.2008.07.023 Verma, 2009, Quality by design approach to understand the process ofnanosuspension preparation, Int. J. Pharm., 377, 2185, 10.1016/j.ijpharm.2009.05.006 Verma, 2009, Scanning probe microscopy method for nanosuspension stabilizer selection, Langmuir, 25, 12481, 10.1021/la9016432 Verma, 2011, Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening, Int. J. Pharm., 406, 145, 10.1016/j.ijpharm.2010.12.027 Wu, 2011, Physical and chemical stability of drug nanoparticles, Adv. Drug. Deliv. Rev., 63, 456, 10.1016/j.addr.2011.02.001